Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
US FDA approves expanded use of Mirum`s liver disease drug
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results
Mirum Pharma to Announce Fourth Quarter and Year-End 2023 Financial Results
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)